As 2022 comes to an end, we wanted to reflect on another year of great advocacy for people living with asthma and allergies. Our community's voices are so powerful. Together, we make a huge difference! Take a look at AAFA's policy and advocacy accomplishments this year and where we're headed in 2023.
|
|
|
Seasonal Asthma and Allergy Friendly Tips
This time of year, you can find asthma and allergy triggers in many places and gatherings. But you can manage asthma and allergies with confidence. See our asthma and food allergy tips for ways to help you prevent symptoms this season.
|
|
|
|
As we head into the new year, trees in many parts of the United States are preparing to produce pollen. In some states, tree pollen appears as early as January and will continue to peak through May. Learn more about tree pollen allergy and how you can start preparing now so you'll have relief this winter and spring.
|
|
|
Carla with her daughter, Keisha
Keisha was known for her shining spirit and heart for service. She actively volunteered in her community and church and excelled in her work at the Federal Aviation Administration. But her life was suddenly cut short when she was only 34 years old due to a severe asthma attack. Following Keisha's giving spirit, her mother, Carla, is raising awareness of asthma and allergies so no other lives are lost due to asthma.
You can also follow Carla and Keisha's examples by helping improve the lives of people with asthma and allergies through AAFA. Your generous support makes it possible for us to provide life-saving and life-changing programs for the more than 60 million people living with asthma and allergies in the United States. AAFA’s evidence-based information and programs promote better understanding of these diseases to empower people with the resources they need to live a full life.
Your gift will help us promote awareness and understanding. There’s still time to make your tax-deductible gift in 2022. Will you consider donating today?
|
|
|
|
Our work is made possible by collaborating with sponsors and supporters. AAFA’s corporate members, sponsors, and supporters help make our mission a reality through collaborative initiatives in patient education, research, advocacy, and more. AAFA is grateful for support from the following companies and organizations:
|
|
|
People with a latex allergy have to be cautious when using medical equipment. Many items may contain latex. Dr. John James responds to this question about neoprene and latex.
AAFA's Ask the Allergist explains why these are not the same and why it's important to take your asthma medicine as prescribed for better asthma management.
There are nine influenza vaccines that have been approved by the U.S. FDA for the 2022-2023 flu season. These vaccines are all quadrivalent. This means that they protect against four different and common strains of influenza.
|
|
|
If you have a question about asthma or allergies, you can send it to our Ask the Allergist service. We will respond in January after our winter break.
|
|
|
"For the last 20 years, I have been frequently dependent on steroids to treat asthma flares, and not one doctor ever talked with me about possible long-term side effects."
"I have severe persistent asthma...I still struggle to breathe daily and just got out of ICU. The pulmonologist in ICU suggested I may be a candidate for bronchial thermoplasty. Does anyone have any experience or advice with bronchial thermoplasty?"
An AAFA community member recently shared their experience on a new biologic, as well as how they managed the insurance process. Visit our community to celebrate their success and share your personal experience.
|
|
|
Would you like to connect with other people who know what it is like to live with asthma or allergies? Join our online community for support.
|
|
|
If you are a health care professional treating someone with chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU), join us for our upcoming CME program. The live program, “The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting Agents,” will air on Jan. 9, 2023, at 3 p.m. ET. Our expert panel will discuss:
-
The relationship between triggers of CIndU and underlying pathophysiologic pathways
-
A comprehensive approach to the diagnosis of urticaria
-
Optimizing treatment of CSU and CIndU
-
And much more
|
|
|
Check out our previous issues to learn about AAFA's new website, the latest asthma and allergy research, and more.
|
|
|
|
|
